<DOC>
	<DOCNO>NCT00610493</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Avastin ( bevacizumab ) Torisel ( temsirolimus ) give , combination , patient advance cancer spread unable surgically remove . The safety drug combination also study .</brief_summary>
	<brief_title>Bevacizumab Temsirolimus Patients With Advanced Malignancy</brief_title>
	<detailed_description>The Study Drugs : Bevacizumab design prevent slow growth cancer cell block growth blood vessel supply nutrient necessary tumor growth . Temsirolimus design block growth cancer cell , may cause cancer cell die . Study Groups : If find eligible take part study , assign dose level bevacizumab temsirolimus combine , base join study . Up 13 dose level study drug combination test . Three ( 3 ) participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose study drug combination find . If choose enroll expansion group patient treat high tolerable dose study drug combination find , require undergo add testing , follow : - You additional blood drawn ( 2 teaspoon time ) Cycle 1 . This blood drawn begin take study drug ; Day 1 1 , 4 , 8 , 24 hour start first infusion ; Day 8 Cycle 1 ; Day 15 Cycle 1 ; end Cycle 1 . The blood use see study drug combination act body learn effect cancer cell . - You 2 tumor biopsy perform . These sample use see study drug combination act body learn effect cancer cell . These tumor biopsy perform screen visit end Cycle 1 . To perform tumor biopsy , affect area numb anesthetic tumor tissue remove small knife . - You extra image scan perform use see study drug combination may affect blood vessel supply nutrient oxygen cancer . A DCE-MRI scan perform screen visit , 24-48 hour start Cycle 1 , end Cycle 1 . Like regular MRI scan , DCE-MRI scan involves pass part body long , narrow tube scanner open end . Study Drug Administration : Bevacizumab temsirolimus give `` cycle . '' Cycles 21 day long longer , depend side effect may experience . Bevacizumab give vein Day 1 cycle . On Day 1 Cycle 1 , receive 90 minute . If tolerate well Cycle 1 , receive 60 minute Cycle 2 . If tolerate well Cycle 2 , receive 30 minute Cycle 3 . It continue give 30 minute Cycle 4 cycle , long still tolerate well . Also , first dose well tolerate , may give remain dos Bevacizumab doctor 's office near hometown . Temsirolimus give vein Days 1 , 8 , 15 cycle . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute Days 8 15 Cycle 1 30 minute cycle , long still tolerate well . Also , first dose well tolerate , may give remain dos Temsirolimus doctor 's office near hometown . Study Visits : You physical exam blood drawn ( 1 tablespoon time ) routine test Days 7 14 Cycle 1 . During rest cycle , physical exam blood drawn ( 1 tablespoon time ) routine test every 3 week . The status disease check CT MRI scan every 2 cycle , start Cycle 2 . Length Study Participation : You may continue receive additional cycle study drug , unless cancer get bad intolerable side effect occur . In case , take study . Once participation study , receive standard-of-care follow-up disease . This investigational study . Bevacizumab temsirolimus commercially available . Bevacizumab FDA approve treatment colorectal cancer type lung cancer . Temsirolimus FDA approve treatment kidney cancer spread . The combination bevacizumab temsirolimus FDA approve . At time , use research . Up 183 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces CR rate least 10 % improve survival least three month . 2 . Patients least four week last day therapeutic radiation cytotoxic chemotherapy antibody therapy , least five halflives noncytotoxic target biologic therapy . Patients may receive palliative radiation immediately ( ) treatment provide radiation target lesion available . 3 . ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 4 . Patients must allowable organ marrow function define : absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=50,000/mL ; creatinine &lt; /= 3 X ULN ; total bilirubin &lt; /= 3.0 ; AST ( SGOT ) /ALT ( SGPT ) &lt; /= 5 X ULN ; fast level total cholesterol 350mg/dL ; triglyceride level 400mg/dL . 5 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day last dose . 6 . Ability understand willingness sign write informed consent document 7 . Patients may receive investigational agent and/or concurrent anticancer agent therapy . 1 . Patients hemoptysis within 28 day prior enter study . 2 . Patients clinically significant unexplained bleeding within 28 day prior enter study 3 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg medication ) . 4 . Patients clinically significant cardiovascular disease : History CVA within 6 month Myocardial infarction unstable angina within 6 month Unstable angina pectoris 5 . Pregnant lactating woman . 6 . History hypersensitivity bevacizumab , murine product , component formulation . 7 . History hypersensitivity Temsirolimus metabolite ( include sirolimus ) , polysorbate 80 , component formulation 8 . Patients take CYP3A4 inducer and/or inhibitor . Please see section 3.2 protocol detail . If patient history take CYP3A4 inducer and/or inhibitor prior enrollment protocol , strongly recommend patient stop drug wait least 5 halflives say drug initiate therapy protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Avastin</keyword>
	<keyword>Torisel</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>dynamic contrast-enhanced magnetic resonance imaging</keyword>
	<keyword>DCE</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>MRI</keyword>
</DOC>